MVMD.CN down 33.33% to C$0.01 on CNQ: Mountain Valley MD Holdings Inc. risk review

MVMD.CN stock fell 33.33% to C$0.01 on the CNQ during market hours on 14 Feb 2026. Trading volume reached 72,041.00 shares, below the 50-day average of 146,176.00. The drop extended a one-month slide of 50.00% and pushed the year-to-date loss to 33.33%. Investors face tight liquidity, negative earnings per share of -0.02, and a market cap of C$3,523,550.00 as the company operates in the Canadian healthcare specialty drug sector.

MVMD.CN stock: intraday price action and volume

MVMD.CN stock opened at C$0.015 and traded between C$0.01 and C$0.015 today. Volume was 72,041.00, about 0.49 times the average, signaling lower liquidity. The stock sits at its year low of C$0.01 and well below the 50-day average price of C$0.015.

Why MVMD.CN stock fell today

The decline tracks weak fundamentals and sparse news flow for Mountain Valley MD Holdings Inc. Market participants cite negative EPS and thin float as primary drivers. The company’s small market cap, C$3,523,550.00, magnifies order-driven moves and amplifies drops on modest sell orders.

Fundamentals and valuation for Mountain Valley MD Holdings Inc.

Mountain Valley MD (MVMD.CN) reports EPS of -0.02 and a negative P/E ratio of -0.47. Price-to-sales stands at 74.97, and price-to-book is 2.68. Current ratio is healthy at 7.83, but cash per share is only 0.00 to two decimals as C$0.00 when rounded, reflecting tight operating scale. These metrics show high valuation multiples versus earnings and limited revenue per share.

Technicals, liquidity and sector context

Technically, RSI sits at 44.11, ADX reads 11.37 indicating no strong trend, and ROC is -33.33%. Average volume for the healthcare peer group is far higher than MVMD.CN’s 72,041.00. The Canadian healthcare sector shows a one‑day move of -6.24% overall, exposing MVMD.CN to sector volatility and investor risk aversion.

Meyka AI grade and MVMD.CN stock forecast

Meyka AI rates MVMD.CN with a score out of 100: 63.03 / 100, Grade B, Suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly C$0.01, quarterly C$0.02, and yearly C$0.00731. Relative to the current price of C$0.01, the quarterly projection implies an upside of 100.00%, while the yearly projection implies a downside of 26.94%. Forecasts are model-based projections and not guarantees.

Analyst outlook, price targets and risks

Market-grade data shows a company rating of C- and a recommendation of Strong Sell on 13 Feb 2026, reflecting weak profitability ratios. We set a conservative short-term price target range of C$0.00 to C$0.03, and a downside risk to C$0.01 given current liquidity. Key risks include continued cash burn, low revenue per share, extended receivables days of 621.28, and limited analyst coverage.

Final Thoughts

Key takeaways for MVMD.CN stock: the share price dropped to C$0.01, a one-day fall of 33.33%, on relatively low liquidity of 72,041.00 shares traded. Fundamentals remain weak, with EPS at -0.02 and a negative P/E. Meyka AI’s model gives mixed signals: a quarterly projection of C$0.02 implies a potential 100.00% upside from today’s price, while the yearly projection of C$0.00731 implies a 26.94% downside. Our view frames MVMD.CN as a high‑volatility, speculative holding in the Drug Manufacturers – Specialty & Generic industry. Investors should weigh the small market cap of C$3,523,550.00, stretched valuation metrics such as price-to-sales 74.97, and sector volatility before trading. Meyka AI’s real-time tools flag liquidity and earnings risk, and we recommend monitoring corporate updates, volume spikes, and any licensing news that could change the outlook. Forecasts are model-based projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.